Table 8.
Mechanisms of resistance to imipenem-relebactam
| Type | Organism | Mechanism(s) | Minimum Inhibitory Concentration of Isolatea | Reference |
|---|---|---|---|---|
| Survey | K pneumoniae | KPC, loss of ompK36 | 8 | 184 |
| Survey | K pneumoniae | Overexpression of KPC-2, TEM-1, SHV-12, loss of ompK35 and ompK36 | 512 | 186 |
| Survey | K pneumoniae | KPC-3 TEM-1/SHV-11, loss of ompK35 and ompK36 | 8 | 186 |
| Survey | S marcescens | SME-1 | 4 | 190 |
| Survey | P aeruginosa | PDC, loss of oprD | 8 | 184 |
| Survey | P aeruginosa | Hyperexpression of PDC, loss of oprD | 8 | 184 |
| Survey | P aeruginosa | GES-5 | >8 | 53 |
Relebactam is maintained at 4 μg/mL when in combination with imipenem.81
P aeruginosa breakpoint: resistant ≥8 μg/mL.
Enterobacterales breakpoint: resistant ≥4 μg/mL.
a
The MIC values for the isolate represent the MIC values obtained for either a clinical isolate obtained from a patient in a case study or part of a surveillance study or a laboratory-selected strain.
Data from Clinical and Laboratory Standards Institute (CLSI). M100: Performance Standards for Antimicrobial Susceptibility Testing. 30th ed.; 2020.